DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk stops Ozempic kidney trial after early signs of success
▼ + stars: | 2023-10-10 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

Pens for the diabetes drug Ozempic sit on a production line to be packaged at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. Novo said the trial would be halted almost a year early based on a recommendation from the independent data monitoring board overseeing the study. Independent monitors can recommend stopping a trial early if there is clear evidence that a drug was going to succeed or fail based on interim analyses. Semaglutide is also the active ingredient in Novo Nordisk's powerful weight-loss drug Wegovy. Novo's success has also created an economic boom for Denmark, according to Danish economists, analysts, and executives at the Novo Nordisk Foundation.

Persons: Tom Little, Novo, Danish drugmaker, Wegovy, Emily Field, Patrick Wingrove, Sriparna Roy, Bill Berkrot Organizations: REUTERS, Novo Nordisk, Barclays, Novo Nordisk Foundation, Thomson Locations: Hillerod, Denmark, Danish, New York, Bengaluru

☆ U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
▼ + stars: | 2023-10-09 | by ( ) www.reuters.com time to read: +2 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. The survey of 502 employers by Accolade (ACCD.O), a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now. Nearly all the companies that are covering GLP-1 drugs plan to keep covering them next year, according to the survey. Employers that cover weight-loss drugs are facing a spike in their healthcare costs because of the growing popularity of Wegovy. Benefits consultant Aon (AON.N) said 1 percentage point of the 8.5% increase in employer healthcare costs it predicted for next year would be driven by employee take-up of weight-loss drugs.

Persons: Victoria Klesty, Savanta, James Wantuck, Ozempic, Eli Lilly's, Leroy Leo, Shinjini Organizations: REUTERS, Novo Nordisk, Accolade, Employers, Novo, Novo Nordisk's Wegovy, Thomson Locations: Oslo, Norway, August31, Victoria, Novo, Novo Nordisk's, United States, Bengaluru

☆ Ozempic isn't the existential threat food companies think it is — yet
▼ + stars: | 2023-10-06 | by ( Jennifer Ortakales Dawkins | ) www.businessinsider.com time to read: +6 min

Food companies fear soaring Ozempic sales could hurt their bottom lines. AdvertisementAdvertisementExecutives at America's biggest food companies can't stop talking about Ozempic . And early data suggests that Ozempic sales will have some impact on the food industry. AdvertisementAdvertisementFor example, if consumers begin to prefer smaller portions, food companies have time to adjust their package sizes, and restaurants have time to modify their menus. "This is not an existential threat to the food industry," he said.

Persons: —, Doug McMillon, Arun Sundaram, Morgan Stanley, Walmart's John Furner, Steve Cahillane, Rice Krispies, Jefferies, Sundaram, David M, Gordon, Ozempic Organizations: Service, America's, Nordisk, North, Walmart, Bloomberg, Wall, Cheesecake

☆ Researchers link popular weight loss drugs to serious digestive problems for ‘hundreds of thousands’ worldwide
▼ + stars: | 2023-10-05 | by ( Brenda Goodman | ) edition.cnn.com time to read: +11 min

They can help people with diabetes control their blood sugar and lead to substantial weight loss for people with or without diabetes. Liraglutide was FDA approved as a weight loss medicine since 2014. What’s been less clear is whether patients taking these drugs for weight loss may have the same serious side effects. CNN reached out to Novo Nordisk, the manufacturer of both injectable weight loss drugs examined in this study, for comment. Sodhi said they started the man on a medication that treats stomach paralysis, “and he got a lot better,” Sodhi said.

Persons: Ozempic, ”, Mahyar, —, It’s, Liraglutide, it’s, Mohit Sodhi, Sodhi, Ian Musgrave, Musgrave, What’s, “, ” Sodhi, Dr, Sanjay Gupta Organizations: CNN, University of British, US Food and Drug Administration, FDA, “, University of Adelaide, Science Media Centre, BMI, Novo Nordisk, CNN Health Locations: University of British Columbia, Australia, Novo

☆ With Ozempic on the rise, food companies develop a plan
▼ + stars: | 2023-10-05 | by ( Danielle Wiener-Bronner | ) edition.cnn.com time to read: +5 min

“If they switch to different types of nutrients … we switch to different types of nutrients,” he said. Drugs like Ozempic could change how people eat, affecting food sellers. Big food companies are constantly evolving their products to adapt to consumer trends. And with wellness top of mind for many — not just people taking semaglutide drugs — companies have already tweaked their products in an effort to appeal to health-conscious consumers. “And then what is the churn rate?” To adapt to a possible shift, companies should be “planning for different scenarios,” she said.

Persons: Sean Connolly, “, ” Connolly, ” Conagra, Duncan Hines, Marie Callender’s, Jaap Arriens, ”, Bernstein, Alexia Howard, ” Howard, John Furner, Morgan Stanley, Pamela Kaufman, Ding Dongs, Mark Smucker, Jody Dushay, “ Dieticians, Deidre McPhillips Organizations: New, New York CNN, Wall Street, Healthy, PepsiCo, Coca, Walmart, Bloomberg, CNN, Companies, Brands, Harvard Medical School Locations: New York

☆ Weight loss drugs may be linked to stomach paralysis, other rare but severe issues, study says
▼ + stars: | 2023-10-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Blockbuster weight loss and diabetes drugs like Wegovy and Ozempic may be associated with an increased risk of three rare, but severe, stomach conditions in non-diabetic patients, according to a new epidemiological study released Thursday. Their research is the first large, population-level study to examine the risk of serious stomach conditions in non-diabetic patients specifically using GLP-1s for weight loss. People with diabetes are also at increased risk of experiencing stomach paralysis and pancreatitis overall, even without the treatments.

Persons: semaglutide, –, Mohit Sodhi Organizations: Blockbuster, JAMA, Novo Nordisk, University of British Columbia, Nordisk Locations: U.S

☆ Novo Nordisk's Wegovy bonanza looms large in Denmark
▼ + stars: | 2023-10-05 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

COPENHAGEN, Oct 5 (Reuters) - The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk (NOVOb.CO), but also for its home country of Denmark. Interviews with Danish economists, analysts, and executives at the Novo Nordisk Foundation which controls Novo highlight the benefits to the economy from jobs to private wealth - but also the potential pitfalls of relying on a single, outsized company. Record profits for Novo are projected to generate returns for the Foundation of more than $12 billion in coming years. Novo Nordisk added 3,500 jobs in Denmark in 2022, bringing the total in the country to 21,000 employees, out of 59,000 worldwide, a company spokesperson said. Before Wegovy, "we used to be kind of, 'Isn't Denmark the place where Stockholm is the capital?'"

Persons: Danes, Lars Skovgaard Andersen, Lars Christensen, Wegovy, Mads Krogsgaard Thomsen, " Thomsen, Moller, Thomsen, Melinda Gates, Rasmus Kristian Feldthusen, Maggie Fick, Jacob Gronholt, Alexander Smith, Josephine Mason, Michele Gershberg, Catherine Evans Organizations: Novo Nordisk, Novo Nordisk Foundation, Danske Bank, Copenhagen Business School, Novo, Foundation, Reuters, Novo Holdings, Carlsberg, Maersk, U.S, Melinda Gates Foundation, UK's Wellcome Trust, Wegovy, University of Copenhagen, Nokia, Pedersen, Thomson Locations: COPENHAGEN, Denmark, Stockholm, Copenhagen, Danish, Novo, Europe, North America, Asia, OUTGROWING DENMARK, Finland

Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris (VTRS.O), to review the validity of the Wegovy and Ozempic patents. A spokesperson for Novo Nordisk said the company will "vigorously defend" its intellectual property. Novo has filed several U.S. patent lawsuits against companies including Pennsylvania-based Viatris that are seeking to market generic versions of the drugs. Viatris has separately asked a West Virginia federal court to invalidate the patents as part of the litigation.

Persons: Tom Little, Wegovy, Ozempic, Mylan, Viatris, Novo's Wegovy, Novo, Blake Brittain, Patrick Wingrove, Will Dunham, David Bario Organizations: Novo Nordisk, Danish, REUTERS, Rights, U.S . Patent, Mylan Pharmaceuticals, Viatris, West, Thomson Locations: Copenhagen, Denmark, Pennsylvania, West Virginia, Washington, New York

☆ Airlines want you to lose weight. Ozempic could save them millions.
▼ + stars: | 2023-10-02 | by ( Kylie Kirschner | ) www.businessinsider.com time to read: +4 min

Airlines are consistently looking for ways to reduce plane weight to increase fuel efficiency. The rise in popularity of weight loss drugs like Ozempic and Wegovy could benefit airlines. AdvertisementAdvertisementThe recent boom of Ozempic, Wegovy, and other buzzy weight-loss drugs could do more than just help people lose weight — it could help the airline industry save money on fuel. Insider reported in 2021 that the average weight of passengers had increased — American Airlines told Insider at the time that their average passenger was eight pounds heavier, at 182 pounds in summer and 187 pounds in winter. Both American and Southwest Airlines previously told Insider that they use data from the CDC to calculate passenger weight.

Persons: —, Sheila Kahyaoglu, liraglutide —, they've, Elon Musk, Boris Johnson, Amy Schumer, Charles Barkley, Sharon Osbourne Organizations: Service, Airlines, FAA, Jefferies, United Airlines, Southwest Airlines, CDC Locations: York City

☆ Airlines might be quietly loving the Ozempic craze. The drugs could save United $80 million a year if each passenger dropped 10 pounds, one analyst estimated.
▼ + stars: | 2023-10-02 | by ( Kylie Kirschner | ) www.businessinsider.com time to read: +4 min

The rise in popularity of weight loss drugs like Ozempic and Wegovy could benefit airlines. One analyst estimated United would save $80 million a year if every passenger lost 10 pounds. AdvertisementAdvertisementUsing United Airlines as a model, Kahyaoglu estimated that if each passenger weighed 10 pounds less on average, the weight savings would equal around 1,790 pounds per flight. Insider reported in 2021 that the average weight of passengers had increased — American Airlines told Insider at the time that their average passenger was eight pounds heavier, at 182 pounds in summer and 187 pounds in winter. Both American and Southwest Airlines previously told Insider that they use data from the CDC to calculate passenger weight.

☆ Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
▼ + stars: | 2023-09-27 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

U.S. health care providers wrote more than nine million prescriptions for Ozempic, Wegovy and similar diabetes and obesity drugs during the last three months of 2022, according to a new analysis released Wednesday. Among the other drugs prescribed are Eli Lilly's diabetes drug Mounjaro and an older GLP-1 drug from Novo Nordisk called Saxenda, which isn't as effective for weight loss as Ozempic and Wegovy. Ozempic's list price tops $935 per monthly package, and its weight loss counterpart Wegovy is about $1,300. Other drugmakers are jockeying to capitalize on the budding weight loss industry. And analysts say Eli Lilly's Mounjaro has the potential to overtake drugs from Novo Nordisk after its approved in the U.S. for weight loss.

Persons: Eli Lilly, Eli, Elon Musk, Eli Lilly's Mounjaro Organizations: Novo Nordisk, Pharmacy, Health, National Institutes of Health Locations: Provo , Utah, U.S

☆ Exclusive: U.S. FDA found lapses at Novo's main U.S. factory in May 2022 -report
▼ + stars: | 2023-09-20 | by ( Maggie Fick | ) www.reuters.com time to read: +4 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. A Form 483 is a type of agency report containing "observations" that FDA inspectors "deem to be objectionable". The FDA did not immediately respond to a request for comment on the report, but usually does not comment on inspections. The report from the May 2022 inspection shows that FDA officials found the factory had failed to include one type of bacteria, abbreviated as B. cepacia, on its list of "objectionable organisms". Analysts at Barclays and Jefferies said in notes this week that, although investors may be concerned by news of potential manufacturing issues, they saw minimal impact on Novo's production of semaglutide.

Persons: Andrew Kelly, Clayton, Jefferies, Steven Lynn, Maggie Fick, Josephine Mason, Mark Potter Organizations: Food and Drug Administration, FDA, REUTERS, Novo Nordisk, Reuters, U.S . Food, Drug Administration, Barclays, Manufacturing, Thomson Locations: White Oak , Maryland, U.S, North America, Clayton , North Carolina

☆ The risks to alcohol and food stocks from Ozempic-like weight loss drugs
▼ + stars: | 2023-09-20 | by ( Paulina Likos | ) www.cnbc.com time to read: +9 min

The rise of new anti-obesity medications could result in less alcohol consumption, impacting Club name Constellation Brands (STZ). The risk already seems to be playing out in food stocks with exposure to snacks and junk food. We don't think Constellation Brands stock will suffer the same fate as shares of leading snack food companies like J.M. Key points The increasing popularity of new diabetes/weight loss drugs could curtail consumer appetite for junk food and alcohol. Constellation Brands (STZ), the Club name behind the Mexican beers Corona and Modelo, should be able to weather any such headwind.

Persons: Eli Lilly, it's, Mills, Lilly, Jim Cramer, Mounjaro, Morgan, Morgan Stanley, AOMs, Jefferies, Jim Cramer's, Jim, Gabby Jones Organizations: Constellation Brands, Corona, Modelo, Pacifico, Nordisk, Ozempic, Club, Novo Nordisk, Brands, Conagra Brands, Constellation, Bud Light, Jefferies, JPMorgan, CNBC, Bloomberg, Getty Locations: U.S, Oro, Brooklyn Borough, New York

New anti-obesity drugs have the potential to transform public health, while obliterating demand for products and services from the medical, food and fitness industries. Drugs developed by Novo Nordisk (NOVOb.CO) and Eli Lilly (LLY.N) appear to be the first truly effective diet treatments. In one clinical trial, patients taking Eli Lilly’s soon-to-be-launched weight-loss drug lost about 50 pounds (23 kg). Only about a third of those who started taking the drugs for obesity were still doing so a year later, according to one analysis. Yet even as Novo, Lilly and others see their addressable markets expand, some companies will see theirs shrink.

Persons: Lilly, George Frey, Eli Lilly, Eli Lilly’s, Novo, Wegovy, Kraft Heinz, Burger, LSEG, Michael Farrell, Zimmer Biomet, Smith, Peter Thal Larsen, Sharon Lam, Oliver Taslic Organizations: Novo Nordisk, Pharmacy, REUTERS, Reuters, TAM, Drugs, Alpha, Reuters Graphics Reuters, Cadbury, Mondelez, Fortune Business, Burger King, KFC, Yum Brands, Centers for Disease Control, Milken Institute, BMJ, Novo, Inspire Medical Systems, Novo Nordisk’s, WW International, Fashion, Thomson Locations: Provo , Utah, U.S, New, United States, Lilly, England

[1/2] A box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly is seen at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. In four separate lawsuits filed in Florida and Texas federal courts, Eli Lilly is seeking orders barring Better Life Pharmacy, ReviveRX, Rx Compound Store and Wells Pharmacy Network from selling tirzepatide, and requesting unspecified damages. Lilly is the only company with U.S. Food and Drug Administration approval to sell tirzepatide drugs. "Defendants use Lilly’s trademark to attract customers and generate revenues and profits, including by passing off as 'Mounjaro' their own unapproved compounded drugs purporting to contain tirzepatide, and doing so for a use for which Mounjaro is not approved, namely weight loss," Eli Lilly said in the lawsuits. However, the agency has said that depending on circumstances, compounded drugs can be made and distributed with fewer restrictions when the original drug appears on its drug shortages list, which Mounjaro currently does.

Persons: Lilly, George Frey, Eli Lilly, Ozempic, Mounjaro, Patrick Wingrove, Bill Berkrot Organizations: Pharmacy, REUTERS, Wells Pharmacy, U.S . Food, Drug Administration, Novo Nordisk, U.S, FDA, Thomson Locations: Provo , Utah, U.S, Florida, Texas, Indianapolis, Arizona , Florida, Georgia, Minnesota, South Carolina, Utah

☆ Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug
▼ + stars: | 2023-09-19 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly on Tuesday sued 10 medical spas, wellness clinics and compounding pharmacies across the U.S. for allegedly selling cheaper, unauthorized versions of the company's diabetes drug Mounjaro. Eli Lilly specifically accuses the spas, clinics and compounding pharmacies of marketing and selling "compounded" drug products that claim to contain tirzepatide, the active ingredient in Mounjaro. Compounded drugs are custom-made versions of a treatment that are not approved by the U.S. Food and Drug Administration. The FDA has not issued a warning about compounded versions of tirzepatide. However, Mounjaro, Ozempic and Wegovy have all been in short supply in the U.S. since last year, according to the FDA's database.

Persons: Eli Lilly, Eli Lilly grapples, Ozempic Organizations: Novo Nordisk, Pharmacy, U.S . Food, Drug Administration, FDA Locations: Provo , Utah, U.S, Florida , Texas , Arizona, Georgia, Minnesota, South Carolina, Utah, Florida

☆ Novo Nordisk shares fall after media report about quality lapses at U.S. plant
▼ + stars: | 2023-09-18 | by ( ) www.reuters.com time to read: +1 min

Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo Acquire Licensing RightsCompanies Novo Nordisk A/S FollowCOPENHAGEN, Sept 18 (Reuters) - Novo Nordisk's (NOVOb.CO) shares fell on Monday after financial news agency MarketWire reported that U.S. drug regulators had recently issued a report detailing quality control lapses at the group's Clayton, North Carolina plant, citing sources. Novo Nordisk declined to comment on the report, but said in an emailed statement that the site was "running and producing for the market". MarketWire did not specify when the FDA inspection occurred. According to the FDA, a Form 483 is a type of agency report containing "observations" that FDA inspectors "deem to be objectionable".

Persons: Jacob Gronholt, Pedersen, MarketWire, Clayton, Maggie Fick, Anna Ringstrom, Jan Harvey Organizations: Novo Nordisk, REUTERS, Reuters, FDA, Thomson Locations: Novo, Copenhagen, Denmark, Clayton, North Carolina

☆ You Won’t Lose Weight on Ozempic Forever
▼ + stars: | 2023-09-18 | by ( Dani Blum | More About Dani Blum | ) www.nytimes.com time to read: +2 min

But doctors say some people seek out these drugs to lose as much weight as possible — and are dismayed and disillusioned when they stop. When they do, they tend to regain the weight they lost. Medications like Ozempic mimic a naturally occurring hormone and slow the emptying of the stomach, so that we feel fuller, faster and for longer. In clinical trials of semaglutide, the compound in Ozempic and Wegovy, people with diabetes have tended to lose less weight, less quickly, than people who did not have the condition, Dr. Hagan said. A small proportion of those who take these drugs won’t lose weight at all, he added.

Persons: ” Ms, Meinecke, Scott Hagan, Hagan, Andrew Kraftson Organizations: University of Washington, Michigan Medicine

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly
▼ + stars: | 2023-09-10 | by ( Maggie Fick | ) www.reuters.com time to read: +5 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. Studies have demonstrated more weight loss than with Wegovy. Novo's type 2 diabetes drug Ozempic has been on the market in Britain since 2019. A Lilly spokesperson declined to comment on Wegovy's launch or when exactly it would launch Mounjaro for diabetes treatment. Studies have shown that, used alongside exercise and lifestyle changes, Wegovy led to 15% weight loss over 68 weeks, while Mounjaro led to more than 22% over 72 weeks.

Persons: Victoria Klesty, Eli Lilly's, Wegovy, Lars Fruergaard Jorgensen, Novo, Lilly, Mounjaro, Ozempic, Eli Lilly, Maggie Fick, Alexander Smith, Catherine Evans Organizations: REUTERS, Wegovy, Economic Co, Development, Reuters, National Health Service, stoke, NHS, Britain's Department of Health, Social Care, Diabetes, UBS, Novo, Thomson Locations: Oslo, Norway, August31, Victoria, Britain, British, Danish, United States, Denmark, Germany, Europe, England

☆ Ozempic, Wegovy may curb drinking, smoking and other addictive behaviors – here's what we know
▼ + stars: | 2023-09-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +7 min

Jaap Arriens | Nurphoto | Getty ImagesHeather Le Biller shed 9 pounds within the first week of taking Novo Nordisk 's blockbuster diabetes drug Ozempic – and then even more as she continued treatment. That means it could take years before the Food and Drug Administration and other regulators worldwide approve drugs like Ozempic and Wegovy as addiction treatments. Jerlhag and her colleagues at the University of Gothenburg in Sweden have studied the effect of GLP-1s on addictive behaviors for more than a decade. "The mechanism in the brain that regulates overeating is important in regulating addictive behaviors as well," Leggio told CNBC. Still, NIDA's Leggio advises against using GLP-1s off-label to reduce addictive behaviors, "simply because there's not enough evidence in humans that they work."

Persons: Jaap Arriens, Heather Le Biller, Ozempic –, Le Biller, they're, Angela Fitch, Brandon Bell, Dr, Lorenzo Leggio, semaglutide, –, Eli Lilly, pharmacologist, Jerlhag, George Frey, NIDA's, Leggio, Steven Batash, Batash, NIDA's Leggio Organizations: Nurphoto, Novo Nordisk, CNBC, Wegovy, Obesity Medicine Association, and Drug Administration, Pharma, National Institute on Drug, University of Gothenburg, Company, Reuters, Brigade, Getty Locations: Riga, Latvia, France, Ozempic, Novo, U.S, Italian, Austin , Texas, Sweden, Provo , Utah, Queens , New York

☆ Obesity drugs’ popularity put a dent in these stocks. Why analysts say they’re still worth buying
▼ + stars: | 2023-09-08 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +7 min

Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won't hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren't buying it. The answer may depend on who you listen to and whether you see GLP-1 drugs as a help or a hinderance to the category. DXCM 3M mountain In the quarter to date, Dexcom shares are down nearly 19%. Dexcom shares are down more than 7% year to date. TNDM 3M mountain Tandem Diabetes shares have fallen significantly this year.

Persons: Ozempic, Danielle Antalffy, Eli Lilly's Mounjaro, hasn't, Dexcom, Piper Sandler, Matt O'Brien, O'Brien, Paresh Dandona, semaglutide, Travis Steed, Steed, — CNBC's Michael Bloom Organizations: UBS, Nordisk's, Novo, New, of Medicine, Tandem Diabetes, Tandem Diabetes Care, Diabetes, Jacobs School of Medicine, Biomedical Sciences, University of Buffalo, Novo Nordisk's, Bank of America Locations: CGMs

Sept 7 (Reuters) - Insulet Corp's (PODD.O) shares hit an over three-year low on Thursday on concerns that strong demand for a new class of diabetes drugs that also aid in weight loss could hit sales of its insulin pumps. CEO James Hollingshead said at the Wells Fargo Healthcare Conference that GLP-1 drugs, which are used to treat type-2 diabetes and obesity, could delay the onset of insulin dependency in diabetes patients. GLP-1s are highly effective weight-loss drugs that some analysts predict could become a $100 billion market by 2030. Shares of Massachusetts-based Insulet fell about 12% to $170.87 and were on track to wipe off about $1.6 billion from the company's market capitalization if losses hold. Insulet manufactures and sells insulin delivery devices, which eliminate the need for multiple daily injections for people with insulin-dependent diabetes.

Persons: James Hollingshead, Novo, Trang Ly, Bhanvi, Anil D'Silva Organizations: Wells, Healthcare Conference, New England, of Medicine, Massachusetts, Thomson Locations: Bengaluru

☆ Blockbuster weight loss drugs Wegovy and Ozempic are being tested to treat addiction and dementia
▼ + stars: | 2023-09-07 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +6 min

Weight loss drugs are being assessed for their ability to treat conditions like dementia and addiction after a landmark study showed that Wegovy helped reduce the risk of heart attacks and strokes. Late-stage trial data released last month by Novo Nordisk indicated that its Wegovy weight loss injection led to "large reductions" in heart failure-related symptoms among at-risk patients. A treatment for drug and alcohol abuseHendershot is one researcher investigating whether the appetite-regulating mechanisms at play in weight loss drugs could be used to treat other conditions such as alcohol and drug addiction. Novo Nordisk's Wegovy and Eli Lilly 's Mounjaro work by imitating a naturally occurring gut hormone that helps regulate appetite in the brain, ultimately leading to weight loss. Implications for reward signalingAdditional possible use cases for weight loss drugs could exacerbate the hurdles already faced by patients using them, however: high costs and supply shortages.

Persons: Wegovy, —, Hendershot, Nordisk's Wegovy, Eli Lilly, Kyle Simmons, Simmons, Ivan Koychev, Harshal Deshmukh Organizations: Bloomberg, Getty, Novo Nordisk, University of North, Chapel Hill, CNBC, Nordisk's, Oklahoma State, Oklahoma State University, University of Baltimore, University of Oxford, University of Hull Locations: Danish, University of North Carolina, Chapel

☆ Business is booming for the maker of weight-loss drugs Wegovy and Ozempic — so much so that it is threatening luxury giant LVMH's crown as Europe's most valuable firm
▼ + stars: | 2023-09-05 | by ( Grace Dean | ) www.businessinsider.com time to read: +3 min

Novo Nordisk has been trading places with LVMH for the title of Europe's most valuable company. The Danish pharmaceutical giant makes the buzzy weight-loss drugs Wegovy and Ozempic. AdvertisementAdvertisementNovo Nordisk, the maker of weight-loss drug Wegovy and diabetes drug Ozempic, has been trading places with French luxury-goods conglomerate LVMH for the title of now Europe's most valuable firm. The UK's NHS recently said that it plans to begin giving out some limited supplies of Wegovy for weight management. Arnault and his family own around 48% of the company's total shares.

Persons: Wegovy, Louis Vuitton, Ozempic, Elon Musk, Bernard Arnault, Arnault Organizations: Novo Nordisk, Morning, Nordisk, Dior, Tiffany, FDA, NHS Locations: LVMH, Danish, GLP, North America

Search resuls for: "Semaglutide"

25 mentions found